

## Special Issue

# Animal Models for Study of Pathophysiological Mechanisms of Hypertension and Its Complications

### Message from the Guest Editors

Since essential hypertension is part of many important health care problems, it is necessary to investigate its mechanisms in animal models. This type of experimental research may have potential clinical importance. This Special Issue will be focused on several important topics, including: **1) The pathophysiological mechanisms responsible for:** i) Blood pressure elevation during hypertension development and maintenance; ii) Organ damage in chronic hypertension; iii) Drug targeting of hypertension and its complications. **2) The participation of:** i) Central and peripheral blood pressure control; ii) Vascular hypertrophy and endothelial damage; iii) Neural, humoral, and endocrine factors; iv) Immune mechanisms. **3) The role of:** i) Altered redox signaling; ii) Chronic inflammation; iii) Microbiome changes; iv) Genetic and/or environmental factors. **4) The progress in:** i) Pharmacological tools for the control of hypertension and organ damage; ii) Genetic modifications to alter blood pressure level; iii) Non-pharmacological interventions attenuating hypertension and its complications.

---

### Guest Editors

Dr. Josef Zicha

Department of Experimental Hypertension, Institute of Physiology of the Academy of Sciences of the Czech Republic, Prague, Czech Republic

Dr. Ivana Vaněčková

Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

---

### Deadline for manuscript submissions

closed (31 August 2022)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/si/109686](https://mdpi.com/si/109686)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 7.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).